The biotech firm targets a threefold increase in manufacturing capacity to strengthen its position in the calf scours market.
ImmuCell Corporation will invest approximately $4.5M to expand its liquid product manufacturing capacity, aiming for more than a threefold increase by the end of 2027. The move follows strategic shifts in late 2025, including leadership changes and sales force expansion to bolster market presence.
The company previously focused on optimizing operations and refining its product pipeline, with recent efforts centered on the calf scours segment. Management highlighted the expansion as a key step to meet growing demand and improve supply chain efficiency.
No immediate market reaction was disclosed in the earnings call summary.